Melola Discovery

← Melola Discovery

Journal SINTA 1

Genetic Polymorphisms Associated with Cyclophosphamide Outcome and Risk of Toxicity in Patients with Lupus Nephritis

ACTA MEDICA INDONESIANA · Vol. 55 No. 3 (2023)

ISSN
2338-2732, 0125-9326
Published
2023-11-01
Publisher
The Indonesian Society of Internal Medicine
Language
eng

Abstract

A 6-month cyclophosphamide induction therapy followed by maintenance therapy every three months is the first-line treatment for Class III, IV, and V lupus nephritis. Among the 139 single nucleotide polymorphisms (SNPs) associated with cyclophosphamide, four SNPs, namely rs4244285, rs4802101, rs7254579 and rs3957356, are related to the response and risk of toxicity in patients with lupus nephritis. Although pharmacogenetic studies in patients with lupus nephritis (LN) have not been conducted previously in Indonesia, data on rs4244285 are available for several ethnic groups, including Papuans, Bataks, Balinese, Dayaks, Javanese, Bugis, Chinese, Timorese and Malays, even though direct evidence in LN patients is less detectable. However, this can be followed up prior to cyclophosphamide therapy based on the identification of genetic markers. Therefore, clinical studies in patients with lupus nephritis are deemed necessary to evaluate the potential of these markers.

Keywords

Collaboration network of the authors

40 authors · 177 co-authorship links · showing the 40 most connected

Hover or tap a name to highlight its co-authors. Double-click to open the author's page.

  • Affiliation unknown
  • Different organisations
  • Same organisation
  • Affiliation unknown
  • Thicker line = more joint articles · bigger circle = more articles
Show as table
Co-authorOrganisationJoint articles
Guntur DarmawanAffiliation unknown5
Roihatul MutiahAffiliation unknown4
Indra WijayaAffiliation unknown3
Amaylia OehadianAffiliation unknown2
Irsan HasanAffiliation unknown1
Trinugroho Heri FadjariAffiliation unknown1
Budi SetiabudiawanAffiliation unknown1
Januar Wibawa MarthaAffiliation unknown1
Syarief HidayatAffiliation unknown1
Mohammad Rizki AkbarAffiliation unknown1
Henny TantonoAffiliation unknown1
Sylvie SakasasmitaAffiliation unknown1
Kevin KarimAffiliation unknown1
Sasfia CandrianitaAffiliation unknown1
Erica Kwan YueAffiliation unknown1
Aang SetiawanAffiliation unknown1
Ria BandiaraAffiliation unknown1
Lisda AmaliaAffiliation unknown1
Bethy S HernowoAffiliation unknown1
Yovita HartantriAffiliation unknown1
Dinar F YaddinAffiliation unknown1
Panji Irani FianzaAffiliation unknown1
Hermin Aminah UsmanAffiliation unknown1
Harjuli Yoy CeanaAffiliation unknown1
Miranti PangastutiAffiliation unknown1
Bachti AlisjahbanaAffiliation unknown1
Dimmy PrasetyaAffiliation unknown1
M Lucky Nurdiansyah PrameswaraAffiliation unknown1
Andri Reza RahmadiAffiliation unknown1
Fransisca FransiscaAffiliation unknown1
Mohammad GhozaliAffiliation unknown1
Sutiadi KusumaAffiliation unknown1
Lusi MersianaAffiliation unknown1
Nadia Gita GhassaniAffiliation unknown1
Yitzchak Millenard SigilipuAffiliation unknown1
Andini KartikasariAffiliation unknown1

Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.

Metadata source: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, first harvested 8 Nov 2026, last seen 8 Nov 2026.
Original metadata (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Genetic Polymorphisms Associated with Cyclophosphamide Outcome and Risk of Toxicity in Patients with Lupus Nephritis</dc:title>
	<dc:creator>Indrawijaya, Yen Yen Ari</dc:creator>
	<dc:creator>Hamijoyo, Laniyati</dc:creator>
	<dc:creator>Artarini, Aluicia Anita</dc:creator>
	<dc:creator>Iwo, Maria Immaculata</dc:creator>
	<dc:subject xml:lang="en-US">Cyclophosphamide</dc:subject>
	<dc:subject xml:lang="en-US">SNP</dc:subject>
	<dc:subject xml:lang="en-US">response</dc:subject>
	<dc:subject xml:lang="en-US">risk of toxicity</dc:subject>
	<dc:subject xml:lang="en-US">renal</dc:subject>
	<dc:description xml:lang="en-US">A 6-month cyclophosphamide induction therapy followed by maintenance therapy every three months is the first-line treatment for Class III, IV, and V lupus nephritis. Among the 139 single nucleotide polymorphisms (SNPs) associated with cyclophosphamide, four SNPs, namely rs4244285, rs4802101, rs7254579 and rs3957356, are related to the response and risk of toxicity in patients with lupus nephritis. Although pharmacogenetic studies in patients with lupus nephritis (LN) have not been conducted previously in Indonesia, data on rs4244285 are available for several ethnic groups, including Papuans, Bataks, Balinese, Dayaks, Javanese, Bugis, Chinese, Timorese and Malays, even though direct evidence in LN patients is less detectable. However, this can be followed up prior to cyclophosphamide therapy based on the identification of genetic markers. Therefore, clinical studies in patients with lupus nephritis are deemed necessary to evaluate the potential of these markers.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2023-11-01</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US">Review Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/2432</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 55 No. 3 (2023): Acta Medica Indonesiana; 343</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/2432/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2023 Yen Yen Ari Indrawijaya, Laniyati Hamijoyo, Aluicia Anita Artarini, Maria Immaculata Iwo</dc:rights>
</oai_dc:dc>